Investors Shareholders

About
Teams
Responsibility
Investments
Media

Current portfolio

Imcyse

Imcyse develops active specific immunotherapies for the treatment and prevention of severe chronic diseases

Sector
Healthcare
Country
Belgium
Fund
LSP 6
Entry
2019
Web
imcyse.com

Sector
Healthcare
Country
Belgium
Fund
LSP 6
Entry
2019
Web
imcyse.com

Latest from Imcyse

22 June 2022
EQT Private Equity to sell Facile.it, Italy’s largest online price comparison platform, to Silver Lake
22 June 2022
EQT Private Equity to acquire SPT Labtech, a fast-growing laboratory automation player focused on low-volume liquid handling technology for GBP 650 million from Battery Ventures
14 June 2022
Partnering to accelerate impact
07 June 2022
EQT Private Equity and Mubadala to acquire Envirotainer, the leading global provider of mission-critical biopharma transport services
01 June 2022
Bulletin from EQT AB’s Annual Shareholders’ Meeting 2022

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of newsRegulatory NewsEQT News

Preferred languageEnglishSwedish

Email address

About

Teams

Responsibility

Investments

Shareholders

Media

Contact

Legal

A purpose-driven global investment organization

© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180